Source: Annual Congress 2004 - Animal models of asthma and chronic bronchitis and their relevance in pulmonary pharmacology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Wollin, D. S. Bundschuh, D. Marx, A. Wohlsen, R. Beume (Konstanz, Germany). Roflumilast inhibits chemokine release in animal models of COPD and asthma. Eur Respir J 2004; 24: Suppl. 48, 4225

Member's Comments

No comment yet.

Related content which might interest you: Inhaled PPAR-r agonist inhibit the airway inflammation in murine model of acute and chronic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 24s Year: 2007 Deficiency of MMP-19 promotes allergen-induced eosinophil burden and airway responsiveness in mice Source: Annual Congress 2007 - Regulation of allergic airway inflammation in animal models of asthma Year: 2007 ST2 gene knockout attenuates allergic airways disease Source: Annual Congress 2006 - Immunological mechanisms in cell recruitment to the lungs Year: 2006 Roflumilast but not dexamethasone or fluticasone reduces neutrophilic airway inflammation and hyperreactivity in a murine influenza-induced asthma exacerbation model Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 The therapeutic efficacy of OAT-889 (dual AMCase/CHIT1 inhibitor) in comparison to montelukast in HDM-induced model of chronic airway inflammation in mice Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 LATE-BREAKING ABSTRACT: The histone-deacetylase-8 selective inhibitor PCI-34051 enhances IFN-λ production in vitro and reduces inflammation in mouse models of rhinoviral infection and rhinovirus-induced exacerbations of asthma in vivo Source: Annual Congress 2013 –Hot topics on airway diseases: new horizons in treatment Year: 2013 Erdosteine affects eicosanoid production in asthma and COPD Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Late-breaking abstract: Inhaled calcium based dry powder inhibits rhinovirus-induced inflammation and exacerbation in a mouse model of allergic airway inflammation Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Roflumilast potently inhibits CXCL1 mediated neutrophil migration in COPD patients Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011 Effect of roflumilast on neutrophilic asthma model Source: International Congress 2017 – Animal models of asthma and allergies Year: 2017 Treatment with gp120 reduces AHR and airway inflammation in a humanized mouse model of asthma bronchiale Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Obesity enhances allergen-induced airway inflammation in a murine model of asthma Source: International Congress 2019 – Modelling and monitoring of airway diseases Year: 2019 Inhibition by roflumilast vs cilomilast of pulmonary leukocyte accumulation and TNFα release in a rat model of LPS-induced pulmonary neutrophilia Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003 An experimental model of rhinovirus-induced COPD exacerbation Source: Annual Congress 2004 - Role of infection in COPD Year: 2004 Allergen-induced airway decorin production is inhibited by budesonide and formoterol in a mouse model of asthma Source: Eur Respir J 2004; 24: Suppl. 48, 690s Year: 2004 Blocking IL-4Ra with dupilumab prevents lung inflammation in a mouse asthma model Source: International Congress 2018 – Identification of therapeutic targets for asthma Year: 2018 PDE-4-inhibitor rolipram supports treg-mediated suppression in a murine model of allergic airway disease Source: Annual Congress 2008 - Risk factors for asthma versus asthma control Year: 2008 A dual role of IL-6 signalling and STAT-3 activation on airway inflammation versus airway hyperresponsiveness in a murine model of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 568s Year: 2002 Pharmacological characterization of the protective effect of mepolizumab against airway hyperresponsiveness in a human ex vivo model of severe asthma Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019 Effects of IL-4Rα blockade on lung inflammation and airway hyperresponsiveness using Mu317RAXMu, a murine surrogate for AMG 317, in a treatment model of cockroach allergen-induced asthma in mice Source: Annual Congress 2008 - Novel mechanisms in the pathogenesis of pulmonary inflammation Year: 2008